Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. Today, in a late-breaking oral presentation at the European Soc...

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Earl...

Novavax Shares Rise 9% Upon Initiating Phase 1/2 COVID-19 Vaccine Clinical Trial

Novavax shares traded higher after the company reported it enrolled the first participants in its Phase 1 clinical study of NVX CoV2373. Novavax Inc. (NVAX:NASDAQ) , which focuses its efforts on developing next-generation vaccines to address infectious diseases, ye...

Biopharma Launches Trial Testing Nitric Oxide as COVID-19 Treatment

The design, timeline and takeaways of Beyond Air's study are presented in a ROTH Capital Partners report. In a June 16 research note, ROTH Capital Partners analyst Scott Henry reported that Beyond Air Inc. (XAIR:NASDAQ) enrolled the first patient in its U.S. clin...

Buzz on the Bullboards: Energy Remains in Focus During Ukraine Crisis

(File image.) The cost of living just keeps getting more expensive. This week saw headlines in the news around the rise in US inflation, up 8.5% over the year to the end of March, to hit its highest rate since 1981. The war in Ukraine drove up energy costs f...

Flying Under the Radar with a Possible COVID-19 Treatment

Investors would think a pharmaceutical company heading into Phase 2b/3 human trials for treating the third most malignant disease after lung cancer and pancreatic cancer would draw eyes from major players. If that same company announced it was embarking on Phase2b/3 human tri...

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Co

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Conducted by Aethlon's Exosome Sciences Subsidiary Source: Gail Dutton of The Life Sciences Report (12/22/15) https://www.thelifesciencesreport.com/pub/na/aethlon-medical...

Buzz on the Bullboards: The calm before another September rally?

It’s the last leg of what looks like an end-of-month rally as investors try to make the most of August’s losses. Traders are neck-deep into a data-heavy week from company fiscal reports that could chart the hike path for interest rates. ...

Buzz on the Bullboards: TSX stocks making headlines this week

The TSX experienced a dynamic week. It opened flat on Monday, but saw a significant jump on Tuesday, driven by a global increase in commodity prices following new monetary stimulus measures in China. However, the energy sector’s decline led to a breather...

Developer of Cannabinoid-Based Drugs to Resume Cancer Pain Trial

Calling this latest development "excellent news," Paradigm Capital has raised its target price on the company's stock. In an April 9 research note, analyst Rahul Sarugaser reported that Paradigm Capital raised its target price on Tetra Bio-Pharma Inc. (TBP:TSX.V; TBPMF...
1 2 3 4 5